Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat ...

Biocon Biologics on Monday said it has launched a biosimilar product to treat certain autoimmune diseases, in the US market. YESINTEK (ustekinumab-kfce), which is approved for the treatment of Crohn’s ...

India-based Syngene International on Monday said it will invest around $50 million on a biologics facility in the Baltimore area, expanding its global manufacturing footprint as companies look to ...

India's Syngene International on Monday said it has acquired its first biologics facility in the United States from ... is strategically located near key biotech hubs in the Northeast US, is expected ...

Syngene International had informed the exchanges late last night that Syngene USA has completed the acquisition of its first biologics site in the USA from Emergent Manufacturing Operations ...

March 10 (Reuters) - India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore, a unit of ...

Syngene International announced acquiring its first biologics facility in the U.S. from Emergent ... four development and manufacturing facilities located in India and North America, offering services ...